Acadia Pharmaceuticals Inc’s recent filing unveils that its EVP, COO, HEAD OF COMMERCIAL Teehan Brendan unloaded Company’s shares for reported $0.17 million on Nov 19 ’24. In the deal valued at $16.81 per share,10,329 shares were sold. As a result of this transaction, Teehan Brendan now holds 62,105 shares worth roughly $1.07 million.
Then, Kihara James sold 4,073 shares, generating $68,467 in total proceeds. Upon selling the shares at $16.81, the PRINCIPAL ACCOUNTING OFFICER now owns 19,863 shares.
Before that, Schneyer Mark C. sold 10,259 shares. Acadia Pharmaceuticals Inc shares valued at $172,454 were divested by the EVP, CHIEF FINANCIAL OFFICER at a price of $16.81 per share. As a result of the transaction, Schneyer Mark C. now holds 53,302 shares, worth roughly $0.92 million.
Guggenheim downgraded its Acadia Pharmaceuticals Inc [ACAD] rating to a Neutral from a a Buy in a research note published on January 03, 2025; the price target was decreased to $20 from $23. Morgan Stanley also remained covering ACAD and has decreased its forecast on August 07, 2024 with a “an Equal-weight” recommendation from previously “an Overweight” rating. BMO Capital Markets started covering the stock on June 27, 2024. It rated ACAD as “an Outperform”.
Price Performance Review of ACAD
On Friday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -1.93% to $17.26. Over the last five days, the stock has lost -7.50%. Acadia Pharmaceuticals Inc shares have fallen nearly -5.94% since the year began. Nevertheless, the stocks have fallen -43.71% over the past one year. While a 52-week high of $31.10 was reached on 01/02/25, a 52-week low of $14.15 was recorded on 01/08/25. SMA at 50 days reached $16.87, while 200 days put it at $16.39.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 16.99, which if violated will result in even more drops to 16.72. On the upside, there is a resistance level at 17.62. A further resistance level may holdings at 17.99. The Relative Strength Index (RSI) on the 14-day chart is 49.66, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.27%. Stochastics %K at 39.00% indicates the stock is a holding.
How much short interest is there in Acadia Pharmaceuticals Inc?
A steep rise in short interest was recorded in Acadia Pharmaceuticals Inc stocks on 2024-12-13, dropping by -0.89 million shares to a total of 9.36 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 10.24 million shares. There was a decline of -9.47%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 12, 2024 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $32.
